Developed Formulas
  • Reduces intestinal inflammation

  • Supports healthy insulin sensitivity

  • Helps protect and restore intestinal barrier function

  • Produces conjugated linoleic acid (CLA)

  • Counteracts gut dysbiosis

Clinical test
In vitro test
Hydrosoluble powder
Allergen Free

Bifidobacterium breve BR03 (DSM 16604)
Bifidobacterium breve B632 (DSM 24706)

Label Claim

Food supplement with probiotic strains.

Effective nutraceutical combination

EFSA Claim: contributes to the maintenance of normal blood glucose levels

Scientific Rationale

Obesity is considered one of the most challenging public health issues today, affecting approximately 1 in 3 individuals worldwide, with 107.7 million obese children in 2017 [1]. Accumulating evidence suggests that gut microbiota is one potential contributor to obesity, along with genetic, behavioral, and environmental factors. Research indicates that individuals, including children, with obesity exhibit alterations in microbiota composition, including decreased biodiversity and richness, as well as changes in specific populations, such as reduced levels of Bifidobacterium.

BIFISLIM® Junior is designed to help restore metabolic balance and reduce chronic inflammation in obese children. It contains Bifidobacterium breve BR03 and Bifidobacterium breve B632, selected for their unique properties, including their ability to colonize the intestines of babies and children, exert immunomodulatory effects, and reduce chronic inflammation [2,3,9]. These probiotics also inhibit various pathogenic microorganisms, including Enterobacteriaceae and different E. coli strains, with BR03 being effective against enterohemorrhagic serotype E. coli O157:H7 [4,5]. Furthermore, B. breve BR03, with a 71% linoleic acid (LA)-to-conjugated linoleic acid (CLA) conversion rate, is a robust CLA producer [6]. In vitro studies have shown that B. breve BR03 can also reduce cholesterol levels. In a clinical study, BIFISLIM® Junior proved effective in enhancing insulin sensitivity during fasting and oral glucose tolerance tests, reducing diastolic blood pressure values, and supporting weight loss in pediatric patients with obesity and insulin resistance. Remarkably, these metabolic benefits persisted even after discontinuing treatment [7,8].


1. GBD 2015 Obesity Collaborators; Afshin A, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6;377(1):13-27. doi: 10.1056/NEJMoa1614362

2. Mogna L. et al. Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014;48 Suppl 1:S37-S39. doi:10.1097/MCG.0000000000000234 

3. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019;  7:214. Doi: 10.35248/2329-8901.19.7.214.

4. Simone M. et al. The probiotic Bifidobacterium breve B632 inhibited the growth of Enterobacteriaceae within colicky infant microbiota cultures. Biomed Res Int. 2014;2014:301053. doi: 10.1155/2014/301053.

5.  Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7

6. Internal Probiotical data

7. Solito A. et al. Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial. Clin Nutr. 2021 Jul;40(7):4585-4594. doi: 10.1016/j.clnu.2021.06.002

8. De Prisco A. et al. An interesting Mechanism of Cholesterol Reduction by Probiotic Strains. Poster from the 15th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health – IPC2022, held in Bratislava on 27-30 June 2022

9. Del Piano M. et al. Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains. J Clin Gastroenterol. 2010; 44 Suppl 1:S42-6. Doi: 10.1097/MCG.0b013e3181ed0e71